Glenmede Trust Co. NA Sells 5,143 Shares of Novo Nordisk A/S (NYSE:NVO)

Glenmede Trust Co. NA reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 1.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 295,430 shares of the company’s stock after selling 5,143 shares during the quarter. Glenmede Trust Co. NA’s holdings in Novo Nordisk A/S were worth $35,177,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in NVO. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC increased its position in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares during the period. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S during the second quarter worth $25,000. Halpern Financial Inc. boosted its holdings in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the period. Finally, Abound Wealth Management grew its position in Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.0 %

NVO opened at $106.12 on Thursday. The firm has a market cap of $476.22 billion, a price-to-earnings ratio of 34.34, a PEG ratio of 1.35 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm’s 50-day simple moving average is $113.80 and its 200-day simple moving average is $128.33. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15.

Analyst Ratings Changes

Several research firms recently weighed in on NVO. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.